Stroke Trials Network of Columbia and Cornell

NINDS卒中试验网络区域协调中心(RCC)应用 马歇尔，埃斯·康诺利，D·莱弗，M·芬克，P·斯蒂格，共同投资 摘要 哥伦比亚大学和康奈尔大学的中风试验网络(STNCC)的主要目标是最大限度地扩大中风临床 纽约的试行招生。哥伦比亚和康奈尔，位于曼哈顿的西侧和东侧， 将分别组成两个枢纽，由布鲁克林的3家医院组成的急诊子网络提供支持 和新泽西州，一个由2个附属学术康复中心组成的恢复子网络 威彻斯特县和新泽西州，以及布鲁克林和纽约西部的4个学术医疗中心。 我们的中枢和卫星在2022年治疗了略高于8700例中风。更重要的是，我们的RCC拥有广泛的 在卒中临床试验中处于领先地位，并在卒中临床试验中处于领先地位 StrokeNet前5年的试验；截至2022年11月，我们的总注册人数为775门，包括 这些试验从前几年开始进入StrokeNet。我们网络中的总体人口统计数据非常有利于 招收服务不足的少数族裔：哥伦比亚有40%的西班牙裔和25%的非裔美国人；康奈尔大学 15%是亚裔，24%是非裔美国人，30%是西班牙裔，12%是其他人。我们的成功部分归功于 高度组织化和互动式的基础设施。我们每月举行视频会议，由PI和 来自所有RCC中心和卫星站点的协调员，以及标准化的日常中风入院筛查 RCC。这些数据以及试验登记在每月的视频会议上进行审查。此外 对于我们在临床试验登记方面的贡献，STNCC在 头10年。兰道夫·马歇尔博士和达娜·莱弗博士一直是StrokeNet指导小组的定期成员 委员会10年。马歇尔博士在NCC执行委员会工作了第一年和第二年。他也是 担任教育和培训核心主席，曾担任联席主席7年。罗恩·拉扎尔博士(现为 UAB)，第一年和第二年在恢复工作组任职，由马歇尔博士接替，后来加入 由Co-I公司的Tomoko Kitago博士于2021年推出。康诺利博士是神经外科顾问小组的成员。我们已经有了 100%参加所有国家会议和电话会议。在创新和临床试验方面 在发展方面，我们的RCC有两个StrokeNet RCT提交和获得资金的区别。 STNCC的联合研究员米切尔·埃尔金德和胡曼·卡迈勒是阿卡迪亚试验的联合PI，这是一项多中心的3期随机对照试验 确定阿匹沙班对隐源性卒中和“心房”患者是否优于标准疗法 心脏病。“兰道夫·马歇尔、桑德·康诺利和罗纳德·拉扎尔是CREST-H研究的联合负责人， CREST-2试验的辅助研究，验证血运重建可以改善AS认知的假设 有脑血流动力学衰竭的高度无症状性颈动脉狭窄患者的亚组。 最后，我们的StrokeNet实习生项目非常成功，11名实习生制作了22篇摘要 奖学金一年内有58篇论文，其中10篇在主要学术领域担任助理教授职位 机构(所有StrokeNet站点)。两人获得了K奖，两人获得了R01。

NINDS Stroke Trials Network Regional Coordinating Center (RCC) application RS Marshall, ES Connolly, D Leifer, M Fink, P Stieg, Co-PIs SUMMARY The Stroke Trials Network of Columbia and Cornell (STNCC) has a primary goal of maximizing stroke clinical trial enrollment for New York. Columbia and Cornell, situated on the west and east side of Manhattan, respectively, will form the two hubs, supported by an Acute Treatment Sub-network of 3 hospitals in Brooklyn and New Jersey, a Recovery Sub-network comprising 2 affiliated academic Rehabilitation Centers in Westchester County and New Jersey, and 4 Academic Medical Centers in Brooklyn and in Western New York. Our hubs and satellites treated just over 8,700 strokes in 2022. More importantly, our RCC has an extensive leadership record in stroke clinical trials, and have the distinction of being the leading enroller in Stroke clinical trials over the first 5 years of StrokeNet; Our total enrollment as of November 2022 was 775 subjects, including the trials rolling into StrokeNet from prior years. The demographics in our network overall are very favorable for enrolling underserved minority populations: Columbia has 40% Hispanic and 25% African American; Cornell 15% Asian, and St. Joseph’s 24% African American, 30% Hispanic, 12% other. Part of our success is due to the highly organized and interactive infrastructure. We hold monthly videoconferences attended by PIs and coordinators from all RCC hubs and satellite sites, and standardized daily stroke admission screening across the RCC. These data as well as trial enrollments are reviewed at the monthly videoconference calls. In addition to our contributions in clinical trial enrollment, the STNCC has been extremely active in leadership roles in the first 10 years. Dr. Randolph Marshall and Dr. Dana Leifer have been regular members of the StrokeNet Steering Committee for 10 years. Dr. Marshall served on the NCC Executive Committee for years 1 and 2. He is also Chair of the Education and Training Core, having served as Co-Chair for 7 years prior. Dr. Ron Lazar (now at UAB), served on the Recovery Working Group in years 1 and 2, and was succeeded by Dr. Marshall, later joined by Co-I Dr. Tomoko Kitago in 2021. Dr. Connolly served on the neurosurgical advisory group. We have had 100% participation at all national meetings and conference calls. In terms of innovation and clinical trial development, our RCC has the distinction of submitting and obtaining funding for two of the StrokeNet RCTs. STNCC Co-Is Mitchell Elkind and Hooman Kamel are Co-PI’s on the ARCADIA trial, a multi-center Phase 3 RCT to determine whether apixaban is superior to standard therapy for patients with cryptogenic stroke and “atrial cardiopathy.” Randolph Marshall, Sander Connolly, and Ronald Lazar are Co-PI’s on the CREST-H study, an ancillary study to the CREST-2 trial, testing the hypothesis that revascularization can improve cognition in as subset of patients with high grade asymptomatic carotid stenosis who have cerebral hemodynamic failure. Finally, our StrokeNet trainee program has been highly successful, with 11 trainees producing 22 abstracts and 58 manuscripts within 1 year of Fellowship, and 10 have Assistant Professor positions at major academic institutions (all StrokeNet sites). Two have had for K-awards and 2 have R01s.